Published in

American Physiological Society, American Journal of Physiology: Cell Physiology, 3(326), p. C880-C892, 2024

DOI: 10.1152/ajpcell.00413.2023

Links

Tools

Export citation

Search in Google Scholar

BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes

Journal article published in 2024 by Lucia Alcober-Boquet, Nico Kraus ORCID, Lisa Sophie Huber, Rajkumar Vutukuri, Dominik C. Fuhrmann ORCID, Claudia Stross, Liliana Schaefer ORCID, Klaus Scholich, Stefan Zeuzem, Albrecht Piiper, Marcel H. Schulz, Jonel Trebicka ORCID, Christoph Welsch ORCID, Cristina Ortiz ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) is a lipid droplet protein primarily expressed in the liver hepatocytes. HSD17B13 is associated with the clinical outcome of chronic liver diseases and is therefore a target for the development of drugs. Here, we demonstrate the promising therapeutic effect of BI-3231 as a potent inhibitor of HSD17B13 based on its ability to inhibit triglyceride accumulation in lipid droplets (LDs), restore lipid metabolism and homeostasis, and increase mitochondrial activity in vitro.